Table 1.
Main clinical characteristics in 162 patients with NPC.
| Characteristics | Total Cohort N (%) |
Training Cohort N (%) |
Validation Cohort N (%) |
|---|---|---|---|
| Gender | |||
| Male | 115 (71.0) | 79 (73.1) | 36 (66.7) |
| Female | 47 (29.0) | 29 (26.9) | 18 (33.3) |
| Age (years) | |||
| ≤41 | 60 (37.0) | 41 (38.0) | 19 (35.2) |
| >41 | 102 (63.0) | 67 (62.0) | 35 (64.8) |
| BMI | |||
| ≤22.3 | 84 (51.9) | 56 (51.9) | 28 (51.9) |
| >22.3 | 78 (48.1) | 52 (48.1) | 26 (48.1) |
| Smoking history | |||
| Non-smoker | 121 (74.7) | 80 (74.1) | 41 (75.9) |
| Current or former smoker | 41 (25.3) | 28 (25.9) | 13 (24.1) |
| Drinking history | |||
| Non-drinker | 143 (88.3) | 98 (90.7) | 45 (83.3) |
| Current or former drinker | 19 (11.7) | 10 (9.3) | 9 (16.7) |
| Histological differentiation | |||
| Undifferentiated | 153 (94.4) | 100 (92.6) | 53 (98.1) |
| Poorly differentiated | 9 (5.6) | 8 (7.4) | 1 (1.9) |
| Clinical stages | |||
| II | 11 (6.8) | 9 (8.3) | 2 (3.7) |
| III | 46 (28.4) | 36 (33.3) | 10 (18.5) |
| IV | 105 (64.8) | 63 (58.4) | 42 (77.8) |
| Tumor stage | |||
| T0–T2 | 38 (23.5) | 27 (25.0) | 11 (20.4) |
| T3–T4 | 124 (76.5) | 81 (75.0) | 43 (79.6) |
| Node stage | |||
| N0–N1 | 70 (43.2) | 47 (43.5) | 23 (42.6) |
| N2–N3 | 92 (56.8) | 61 (56.5) | 31 (57.4) |
| Metastasis stage | |||
| M0 | 77 (47.5) | 54 (50.0) | 23 (42.6) |
| M1 | 85 (52.5) | 54 (50.0) | 31 (57.4) |
| Distant metastasis (One or multiple) |
|||
| Distant lymph nodes | 63 (38.9) | 46 (42.6) | 17 (31.5) |
| Liver | 26 (16.1) | 17 (15.7) | 9 (16.7) |
| Lung | 36 (22.2) | 21 (19.4) | 15 (2.8) |
| Bone | 45 (27.8) | 28 (25.9) | 17 (31.5) |
| Previous chemotherapy | |||
| Radiotherapy | 14 (8.6) | 10 (9.2) | 4 (7.5) |
| Chemotherapy | 73 (45.1) | 49 (45.4) | 24 (44.4) |
| Chemoradiotherpy | 75 (46.3) | 49 (45.4) | 26 (48.1) |
| Recurrence | |||
| Yes | 74 (45.7) | 40 (37.0) | 34 (62.9) |
| No | 88 (54.3) | 68 (63.0) | 20 (37.1) |
| Outcomes | |||
| CR | 1 (0.6) | 1 (0.9) | 0 |
| PR | 52 (32.1) | 45 (41.7) | 7 (13.0) |
| SD | 35 (21.6) | 9 (8.3) | 26 (48.1) |
| PD | 74 (45.7) | 53 (49.1) | 21 (38.9) |
| PD-1 Blockade | |||
| Camrelizumab | 18 (11.1) | 10 (9.3) | 8 (14.8) |
| Toripalimab | 119 (73.5) | 81 (75.0) | 38 (70.4) |
| Pembrolizumb | 3 (1.9) | 3 (2.8) | 0 |
| Sintilimab | 22 (13.5) | 14 (12.9) | 8 (14.8) |